Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Tularik |
---|---|
Information provided by: | Tularik |
ClinicalTrials.gov Identifier: | NCT00043446 |
The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
Condition | Intervention | Phase |
---|---|---|
Ovarian Neoplasms |
Drug: intravenous T900607-sodium |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
United States, California | |
USC Women's and Children's Hospital | |
Los Angeles, California, United States, 90033 | |
Scripps Health Center | |
La Jolla, California, United States, 92037 | |
University of California San Francisco | |
San Francisco, California, United States, 94115 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, New York | |
Roswell Park Cancer Center | |
Buffalo, New York, United States, 14263 |
Study Chair: | Kerrie Boyd | Tularik |
Study ID Numbers: | T-607-005 |
Study First Received: | August 8, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00043446 |
Health Authority: | United States: Food and Drug Administration |
Genital Diseases, Female Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female |
Endocrine System Diseases Urogenital Neoplasms Endocrinopathy Ovarian Diseases Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Adnexal Diseases |